Dabigatran PBS listing expected

A spokesperson for manufacturer Boehringer Ingelheim said they were “extremely confident” it would be listed on 1 September for stroke prevention in patients with non-valvular atrial fibrillation.

A spokesperson for the health department could not confirm the date.

BMS and Pfizer, sponsors of competitor apixaban (Eliquis), also said they were confident of securing a 1 September listing.

Bayer’s competitor product,